TY - JOUR
T1 - Towards personalized nicotinamide mononucleotide (NMN) supplementation
T2 - Nicotinamide adenine dinucleotide (NAD) concentration
AU - Kuerec, Ajla Hodzic
AU - Wang, Weilan
AU - Yi, Lin
AU - Tao, Rongsheng
AU - Lin, Zhigang
AU - Vaidya, Aditi
AU - Pendse, Sohal
AU - Thasma, Sornaraja
AU - Andhalkar, Niranjan
AU - Avhad, Ganesh
AU - Kumbhar, Vidyadhar
AU - Maier, Andrea B.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/4
Y1 - 2024/4
N2 - Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD), which declines with age. Supplementation of NMN has been shown to improve blood NAD concentration. However, the optimal NMN dose remains unclear. This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40–65 years. The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration, blood biological age, homeostatic model assessment for insulin resistance, 6-minute walk test, and 36-item short-form survey (SF-36) were measured at baseline and after supplement. A significant dose-dependent increase in NAD concentration change (NADΔ) was observed following NMN supplementation, with a large coefficient of variation (29.2–113.3%) within group. The increase in NADΔ was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score. The median effect dose of NADΔ for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9–20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5–16.5 nmol/L), respectively. Because of the high interindividual variability of the NADΔ after NMN supplementation, monitoring NAD concentration can provide valuable insights for tailoring personalized dosage regimens and optimizing NMN utilization.
AB - Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD), which declines with age. Supplementation of NMN has been shown to improve blood NAD concentration. However, the optimal NMN dose remains unclear. This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40–65 years. The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration, blood biological age, homeostatic model assessment for insulin resistance, 6-minute walk test, and 36-item short-form survey (SF-36) were measured at baseline and after supplement. A significant dose-dependent increase in NAD concentration change (NADΔ) was observed following NMN supplementation, with a large coefficient of variation (29.2–113.3%) within group. The increase in NADΔ was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score. The median effect dose of NADΔ for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9–20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5–16.5 nmol/L), respectively. Because of the high interindividual variability of the NADΔ after NMN supplementation, monitoring NAD concentration can provide valuable insights for tailoring personalized dosage regimens and optimizing NMN utilization.
KW - Clinical trial
KW - Dietary supplements
KW - NAD
KW - Nicotinamide mononucleotide
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85186750454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186750454&partnerID=8YFLogxK
U2 - 10.1016/j.mad.2024.111917
DO - 10.1016/j.mad.2024.111917
M3 - Article
C2 - 38430946
AN - SCOPUS:85186750454
SN - 0047-6374
VL - 218
SP - 1
EP - 6
JO - Mechanisms of Ageing and Development
JF - Mechanisms of Ageing and Development
M1 - 111917
ER -